In this podcast series on CAR T-cell Therapy, MIDI’s CEO and Co-Founder, Chris Montalbano, discusses his insight into this exciting and rapidly evolving field in cancer treatment.

The first FDA-approved CAR T-cell biopharmaceutical drug was introduced in 2017. Currently there are approximately 10 approved drugs, and the number in  development and FDA approval pipeline is growing exponentially.  This therapy is unique because it specifically targets cancer cells while sparing healthy cells, in contrast to other treatment methods that can kill both. The precision of this approach has generated much excitement within the medical community, as it has the potential to revolutionize cancer treatment.

In this PodCast series, we will be discussing methods which can help mitigate the hurdles of time and cost by allowing the production process to scale in high volume, thus dropping cost per therapy, increasing production turn-around time and making the therapy accessible to a much larger population of patients.  It’s a POC (Point of Care) approach, where the biopharma product is produced at, or near, the patient treatment site. This will provide for true Democratization.

Listen to Episode 1, "Why Democratization and how does CAR T-cell Therapy Compare to Alternative Methods of Cancer Treatment?"